MGC Pharmaceuticals Ltd - phyto-derived medicines producer and developer - Secures an approval in Israel to conduct a phase III clinical trial to evaluate the efficacy and safety of CimetrA as a treatment for moderate hospitalised patients diagnosed with Covid-19. The trial is now scheduled to commence in early April, and will provide essential data to plan for the potential future registration of CimetrA as a drug. The company says it has received two independent ethics committee approvals granted by Rambam and EMMS hospitals, based on the successful completion of the phase II trial.
Current stock price: 4.10 pence, up 2.5% on Monday
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.